Patent clash: Nyxoah (NYXH) sues Inspire Medical over U.S. device patents

Rhea-AI Filing Summary

Nyxoah SA reported that it has filed a patent infringement lawsuit in the United States against Inspire Medical Systems, Inc.. The suit, filed in the District of Delaware, alleges that Inspire’s Inspire IV and Inspire V devices infringe three Nyxoah U.S. patents and seeks injunctive relief and damages. Information about the lawsuit is furnished via a press release attached as Exhibit 99.1 and the lawsuit description is incorporated by reference into Nyxoah’s existing Form S-8 and Form F-3 registration statements.

Insights

Litigation and regulatory analyst

Nyxoah initiates U.S. patent lawsuit over Inspire IV and V devices.

Nyxoah SA has begun patent litigation against Inspire Medical Systems in the U.S. District Court for the District of Delaware. The complaint alleges infringement of three specific U.S. patents tied to devices competing with Nyxoah’s technology.

The company is seeking injunctive relief and damages, indicating it aims both to potentially restrict use of the accused Inspire IV and Inspire V devices and to recover monetary compensation. No damage amounts, timelines, or probability of outcome are discussed in the disclosure.

The lawsuit description is incorporated by reference into multiple Form S-8 and Form F-3 registration statements, meaning ongoing litigation status may be relevant for future securities offerings. Investors will need subsequent company filings to learn about case progress, settlements, or court decisions once they occur.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-40552

NYXOAH SA

(Translation of registrant’s name into English)

Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Nyxoah SA

On September 15, 2025, Nyxoah SA (the “Company”) issued a press release announcing that it has filed a patent infringement lawsuit against Inspire Medical Systems, Inc. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Inspire Patent Infringement Lawsuit

The Company filed a patent infringement lawsuit against Inspire Medical Systems, Inc. alleging that the Inspire IV and Inspire V devices infringe the following three patents held by the Company: U.S. Patent Nos. 8,700,183, 9,415,215, and 9,415,216. The suit was filed in the United States District Court for the District of Delaware, seeking injunctive relief and damages for infringement.

The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

The information included under the heading “Inspire Patent Infringement Lawsuit” shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-285960, 333-283103, 333-261233 and 333-269410) and Form F-3 (Registration Numbers 333-268955 and 333-285982) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

2

Exhibits

99.1 Press Release, dated September 15, 2025

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NYXOAH SA
Date: September 15, 2025	By:	/s/ John Landry
	Name:	John Landry
	Title:	Chief Financial Officer

4

FAQ

What did Nyxoah (NYXH) disclose in its September 2025 Form 6-K?

Nyxoah disclosed that it has filed a patent infringement lawsuit against Inspire Medical Systems, Inc. in the U.S. District Court for the District of Delaware, seeking injunctive relief and damages, and furnished a related press release as Exhibit 99.1 incorporated by reference.

Which Inspire Medical products are involved in Nyxoah’s new patent lawsuit?

Nyxoah’s lawsuit targets Inspire Medical Systems’ Inspire IV and Inspire V devices. The complaint alleges these devices infringe three Nyxoah-held U.S. patents, forming the basis for Nyxoah’s claims for injunctive relief and monetary damages in the District of Delaware action.

Which patents does Nyxoah claim are infringed by Inspire Medical Systems?

Nyxoah alleges infringement of three U.S. patents: Patent Nos. 8,700,183, 9,415,215, and 9,415,216. These patents are identified as being held by Nyxoah and are central to its infringement claims against the Inspire IV and Inspire V devices in the Delaware lawsuit.

What remedies is Nyxoah seeking in its lawsuit against Inspire Medical?

Nyxoah is seeking injunctive relief and damages in its lawsuit. Injunctive relief aims to restrict or stop allegedly infringing activities involving Inspire IV and Inspire V devices, while damages would provide monetary compensation if the court ultimately finds infringement of Nyxoah’s asserted patents.

How is the Inspire patent lawsuit information treated under U.S. securities laws?

The attached press release is furnished, not deemed filed, for Exchange Act Section 18 purposes, limiting certain liabilities. However, the specific “Inspire Patent Infringement Lawsuit” section is incorporated by reference into Nyxoah’s Form S-8 and Form F-3 registration statements from the date of this report.

Which Nyxoah registration statements now incorporate the Inspire lawsuit disclosure?

The lawsuit disclosure is incorporated by reference into Nyxoah’s Form S-8 registration statements 333-285960, 333-283103, 333-261233, 333-269410 and Form F-3 registration statements 333-268955 and 333-285982, becoming part of those documents from the filing date unless later superseded.